Showing 1721-1730 of 2150 results for "".
- Nicox Postpones Nasdaq Listing Due to Market Volatilityhttps://modernod.com/news/nicox-postpones-nasdaq-listing-due-to-market-volatility/2479717/Nicox SA announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time, according to a company news release. The purpose of a Nasdaq l
- Increasing Surgery Volume Will Fuel Single-Use Ophthalmic Surgical Device Markethttps://modernod.com/news/increasing-surgery-volume-will-fuel-single-use-ophthalmic-surgical-device-market/2479784/According to Market Scope research, two factors will drive healthy growth in the single-use ophthalmic surgical product market over the next 5 years: an aging world population, which will lead to steady growth in ophthalmic surgeries, and rising concerns over cross-contamination. Market Sc
- Market Scope Announces Launch of New Website and Entry into Orthopedicshttps://modernod.com/news/market-scope-announces-launch-of-new-website-and-entry-into-orthopedics/2479792/Market Scope announced the launch of its new website and the firm’s entry into orthopedics, its second medical vertical. The new Market-Scope.com emphasizes user experience and features a customized and interactive dashboard where clients can access newsletters, survey results, and repor
- Aussie Researchers Identify New Genetic Markers for Glaucomahttps://modernod.com/news/aussie-researchers-identify-new-genetic-markers-for-glaucoma/2479975/Australian researchers said they have identified 40 new genetic markers that increase a person’s risk of developing glaucoma, pointing to improvements in testing and predicting the risks of getting the eye disease, according to a
- FDA Releases Action Plan to Speed Up Market Entry for Biosimilarshttps://modernod.com/news/fda-releases-action-plan-to-speed-up-market-entry-for-biosimilars/2480010/The FDA unveiled plans Wednesday designed to facilitate the development, approval and market entry of biosimilars in the US. The Biosimilars Action Plan (BAP) “is aimed at promoting competition and affordability across the market for biologics and biosimilar products,” commented FDA C
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
- Market Scope: OCT Market to Generate $632 Million in Revenues in 2018https://modernod.com/news/market-scope-oct-market-to-generate-632-million-in-revenues-in-2018/2480062/Market Scope estimates that the optical coherence tomography (OCT) market will generate $632 million in total manufacturer revenues in 2018, and the market will grow to $797 million by 2023 at a compound annual growth rate of 4.8 percent. Market Scope expects much of this growth to come fr
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- Market Scope: New Products Poised to Drive Glaucoma Pharma Market to $6.6 Billion by 2023https://modernod.com/news/market-scope-new-products-poised-to-drive-glaucoma-pharma-market-to-6-6-billion-by-2023/2480067/The launches of Vyzulta, Rhopressa, and preservative-free formulations promise to boost manufacturers’ revenues during the next 5 years in the global glaucoma pharmaceuticals market. The upswing follows years of declining revenues as branded products lost patent protection and the market s
- Ophthalmic OR Microscope Market to See More Than 6 Percent Growth over Next Five Yearshttps://modernod.com/news/ophthalmic-or-microscope-market-to-see-more-than-6-percent-growth-over-next-five-years/2480110/Market Scope expects the global ophthalmic operating room (OR) microscope market to grow at a healthy pace of more than 6 percent over the next 5 years, as 2018 revenues of $403 million climb to nearly $548 million by 2023. Revenues will rise most sharply in Latin America and other develop